179 related articles for article (PubMed ID: 38193117)
1. Multimodal nanoparticle-containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation.
Truong N; Cottingham AL; Dharmaraj S; Shaw JR; Lasola JJM; Goodis CC; Fletcher S; Pearson RM
Bioeng Transl Med; 2024 Jan; 9(1):e10611. PubMed ID: 38193117
[TBL] [Abstract][Full Text] [Related]
2. Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge.
Truong N; Goodis CC; Cottingham AL; Shaw JR; Fletcher S; Pearson RM
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1128-1141. PubMed ID: 36407956
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis.
Wu Y; He Y; Liu C; Ehle C; Iyer-Bierhoff A; Liu B; Heinzel T; Xing S
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569823
[TBL] [Abstract][Full Text] [Related]
4. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
[TBL] [Abstract][Full Text] [Related]
5. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
Ratay ML; Balmert SC; Bassin EJ; Little SR
Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages.
Chong W; Li Y; Liu B; Zhao T; Fukudome EY; Liu Z; Smith WM; Velmahos GC; deMoya MA; Alam HB
J Surg Res; 2012 Dec; 178(2):851-9. PubMed ID: 22868051
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells.
Chou PJ; Sarwar MS; Wang L; Wu R; Li S; Hudlikar RR; Wang Y; Su X; Kong AN
Cancer Prev Res (Phila); 2023 Jun; 16(6):321-332. PubMed ID: 36867722
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer.
Sankar R; Ravikumar V
Biomed Pharmacother; 2014 Sep; 68(7):865-71. PubMed ID: 25107842
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents.
Li Y; Liu B; Zhao H; Sailhamer EA; Fukudome EY; Zhang X; Kheirbek T; Finkelstein RA; Velmahos GC; deMoya M; Hales CA; Alam HB
Shock; 2009 Nov; 32(5):517-23. PubMed ID: 19295477
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents.
Zhao Y; Zhou P; Liu B; Bambakidis T; Mazitschek R; Alam HB; Li Y
J Surg Res; 2015 Apr; 194(2):544-550. PubMed ID: 25479907
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses.
Bodas M; Mazur S; Min T; Vij N
Respir Res; 2018 Jan; 19(1):2. PubMed ID: 29301535
[TBL] [Abstract][Full Text] [Related]
12. Citrullinated histone H3: a novel target for the treatment of sepsis.
Li Y; Liu Z; Liu B; Zhao T; Chong W; Wang Y; Alam HB
Surgery; 2014 Aug; 156(2):229-34. PubMed ID: 24957671
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured delivery system for Suberoylanilide hydroxamic acid against lung cancer cells.
Sankar R; Karthik S; Subramanian N; Krishnaswami V; Sonnemann J; Ravikumar V
Mater Sci Eng C Mater Biol Appl; 2015 Jun; 51():362-8. PubMed ID: 25842146
[TBL] [Abstract][Full Text] [Related]
14. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
15. Cargo-less nanoparticles program innate immune cell responses to toll-like receptor activation.
Casey LM; Kakade S; Decker JT; Rose JA; Deans K; Shea LD; Pearson RM
Biomaterials; 2019 Oct; 218():119333. PubMed ID: 31301576
[TBL] [Abstract][Full Text] [Related]
16. Effects of Suberoylanilide Hydroxamic Acid (SAHA) on the Inflammatory Response in Lipopolysaccharide-Induced N9 Microglial Cells.
Çelik ZB; Günaydın C
Cureus; 2022 Dec; 14(12):e32428. PubMed ID: 36644097
[TBL] [Abstract][Full Text] [Related]
17. Creating a "pro-survival" phenotype through epigenetic modulation.
Li Y; Liu B; Gu X; Kochanek AR; Fukudome EY; Liu Z; Zhao T; Chong W; Zhao Y; Zhang D; Libermann TA; Alam HB
Surgery; 2012 Sep; 152(3):455-64. PubMed ID: 22938904
[TBL] [Abstract][Full Text] [Related]
18. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans.
Sailhamer EA; Li Y; Smith EJ; Shuja F; Shults C; Liu B; Soupir C; deMoya M; Velmahos G; Alam HB
Surgery; 2008 Aug; 144(2):204-16. PubMed ID: 18656627
[TBL] [Abstract][Full Text] [Related]
19. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.
Reardon B; Beliakova-Bethell N; Spina CA; Singhania A; Margolis DM; Richman DR; Woelk CH
AIDS; 2015 Nov; 29(17):2235-44. PubMed ID: 26258524
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
